Can mammographic and sonographic imaging features predict the Oncotype DX™ recurrence score in T1 and T2, hormone receptor positive, HER2 negative and axillary lymph node negative breast cancers?

Monica Yepes, Ada Pat Romilly, Fernando Collado-Mesa, Jose M Net, Richard Kiszonas, Kristopher Arheart, Daniel Young, Stefan Glück

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

To determine whether mammographic or sonographic features can predict the Oncotype DX™ recurrence scores (RS) in patients with TI–II, hormone receptor (HR) positive, HER2/neu negative and node negative breast cancers. Institutional board review was obtained and informed consent was waived for this retrospective study. Seventy-eight patients with stage I–II invasive breast cancer that was HR positive, HER2 negative, and lymph node negative for whom mammographic and or sonographic imaging and Oncotype DX™ assay scores were available were included in the study Four breast dedicated radiologists blinded to the RS retrospectively described the lesions according to BI-RADS lexicon descriptors. Multivariable logistic regression was used to test for significant independent predictors of low (<18) versus intermediate to high range (≥18). Two imaging features reached statistical significance in predicting low from intermediate or high risk RS: pleomorphic microcalcifications within a mass (P = 0.017); OR 8.37, 95 % CI (1.47–47.79) on mammography and posterior acoustic enhancement in a mass on ultrasound (P = 0.048); OR 4.35, 95 % CI (1.01–18.73) on multivariable logistic regression. A mass with pleomorphic microcalcifications on mammography or the presence of posterior acoustic enhancement on ultrasound may predict an intermediate to high RS as determined by the Oncotype DXTM assay in patients with stage I–II HR positive, HER2 negative, and lymph node negative invasive breast cancer.

Original languageEnglish
Pages (from-to)117-123
Number of pages7
JournalBreast Cancer Research and Treatment
Volume148
Issue number1
DOIs
StatePublished - Jan 1 2014

Fingerprint

Lymph Nodes
Hormones
Breast Neoplasms
Calcinosis
Recurrence
Mammography
Acoustics
Logistic Models
Research Ethics Committees
Informed Consent
Breast
Retrospective Studies

Keywords

  • Breast imaging
  • Imaging correlation
  • Mammography
  • Oncotype DX
  • Oncotype DX recurrence score
  • Ultrasound

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Can mammographic and sonographic imaging features predict the Oncotype DX™ recurrence score in T1 and T2, hormone receptor positive, HER2 negative and axillary lymph node negative breast cancers? / Yepes, Monica; Romilly, Ada Pat; Collado-Mesa, Fernando; Net, Jose M; Kiszonas, Richard; Arheart, Kristopher; Young, Daniel; Glück, Stefan.

In: Breast Cancer Research and Treatment, Vol. 148, No. 1, 01.01.2014, p. 117-123.

Research output: Contribution to journalArticle

@article{4a7eb9384d50415dbbe2fdd4c00a444d,
title = "Can mammographic and sonographic imaging features predict the Oncotype DX™ recurrence score in T1 and T2, hormone receptor positive, HER2 negative and axillary lymph node negative breast cancers?",
abstract = "To determine whether mammographic or sonographic features can predict the Oncotype DX™ recurrence scores (RS) in patients with TI–II, hormone receptor (HR) positive, HER2/neu negative and node negative breast cancers. Institutional board review was obtained and informed consent was waived for this retrospective study. Seventy-eight patients with stage I–II invasive breast cancer that was HR positive, HER2 negative, and lymph node negative for whom mammographic and or sonographic imaging and Oncotype DX™ assay scores were available were included in the study Four breast dedicated radiologists blinded to the RS retrospectively described the lesions according to BI-RADS lexicon descriptors. Multivariable logistic regression was used to test for significant independent predictors of low (<18) versus intermediate to high range (≥18). Two imaging features reached statistical significance in predicting low from intermediate or high risk RS: pleomorphic microcalcifications within a mass (P = 0.017); OR 8.37, 95 {\%} CI (1.47–47.79) on mammography and posterior acoustic enhancement in a mass on ultrasound (P = 0.048); OR 4.35, 95 {\%} CI (1.01–18.73) on multivariable logistic regression. A mass with pleomorphic microcalcifications on mammography or the presence of posterior acoustic enhancement on ultrasound may predict an intermediate to high RS as determined by the Oncotype DXTM assay in patients with stage I–II HR positive, HER2 negative, and lymph node negative invasive breast cancer.",
keywords = "Breast imaging, Imaging correlation, Mammography, Oncotype DX, Oncotype DX recurrence score, Ultrasound",
author = "Monica Yepes and Romilly, {Ada Pat} and Fernando Collado-Mesa and Net, {Jose M} and Richard Kiszonas and Kristopher Arheart and Daniel Young and Stefan Gl{\"u}ck",
year = "2014",
month = "1",
day = "1",
doi = "10.1007/s10549-014-3143-z",
language = "English",
volume = "148",
pages = "117--123",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - Can mammographic and sonographic imaging features predict the Oncotype DX™ recurrence score in T1 and T2, hormone receptor positive, HER2 negative and axillary lymph node negative breast cancers?

AU - Yepes, Monica

AU - Romilly, Ada Pat

AU - Collado-Mesa, Fernando

AU - Net, Jose M

AU - Kiszonas, Richard

AU - Arheart, Kristopher

AU - Young, Daniel

AU - Glück, Stefan

PY - 2014/1/1

Y1 - 2014/1/1

N2 - To determine whether mammographic or sonographic features can predict the Oncotype DX™ recurrence scores (RS) in patients with TI–II, hormone receptor (HR) positive, HER2/neu negative and node negative breast cancers. Institutional board review was obtained and informed consent was waived for this retrospective study. Seventy-eight patients with stage I–II invasive breast cancer that was HR positive, HER2 negative, and lymph node negative for whom mammographic and or sonographic imaging and Oncotype DX™ assay scores were available were included in the study Four breast dedicated radiologists blinded to the RS retrospectively described the lesions according to BI-RADS lexicon descriptors. Multivariable logistic regression was used to test for significant independent predictors of low (<18) versus intermediate to high range (≥18). Two imaging features reached statistical significance in predicting low from intermediate or high risk RS: pleomorphic microcalcifications within a mass (P = 0.017); OR 8.37, 95 % CI (1.47–47.79) on mammography and posterior acoustic enhancement in a mass on ultrasound (P = 0.048); OR 4.35, 95 % CI (1.01–18.73) on multivariable logistic regression. A mass with pleomorphic microcalcifications on mammography or the presence of posterior acoustic enhancement on ultrasound may predict an intermediate to high RS as determined by the Oncotype DXTM assay in patients with stage I–II HR positive, HER2 negative, and lymph node negative invasive breast cancer.

AB - To determine whether mammographic or sonographic features can predict the Oncotype DX™ recurrence scores (RS) in patients with TI–II, hormone receptor (HR) positive, HER2/neu negative and node negative breast cancers. Institutional board review was obtained and informed consent was waived for this retrospective study. Seventy-eight patients with stage I–II invasive breast cancer that was HR positive, HER2 negative, and lymph node negative for whom mammographic and or sonographic imaging and Oncotype DX™ assay scores were available were included in the study Four breast dedicated radiologists blinded to the RS retrospectively described the lesions according to BI-RADS lexicon descriptors. Multivariable logistic regression was used to test for significant independent predictors of low (<18) versus intermediate to high range (≥18). Two imaging features reached statistical significance in predicting low from intermediate or high risk RS: pleomorphic microcalcifications within a mass (P = 0.017); OR 8.37, 95 % CI (1.47–47.79) on mammography and posterior acoustic enhancement in a mass on ultrasound (P = 0.048); OR 4.35, 95 % CI (1.01–18.73) on multivariable logistic regression. A mass with pleomorphic microcalcifications on mammography or the presence of posterior acoustic enhancement on ultrasound may predict an intermediate to high RS as determined by the Oncotype DXTM assay in patients with stage I–II HR positive, HER2 negative, and lymph node negative invasive breast cancer.

KW - Breast imaging

KW - Imaging correlation

KW - Mammography

KW - Oncotype DX

KW - Oncotype DX recurrence score

KW - Ultrasound

UR - http://www.scopus.com/inward/record.url?scp=84921936272&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921936272&partnerID=8YFLogxK

U2 - 10.1007/s10549-014-3143-z

DO - 10.1007/s10549-014-3143-z

M3 - Article

C2 - 25262341

AN - SCOPUS:84921936272

VL - 148

SP - 117

EP - 123

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 1

ER -